Trial Profile
A real life observational study evaluating molecular responses after switching from a standard dose twice daily Nilotinib regimen to a reduced dose once daily schedule in patients with chronic myeloid leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 26 Dec 2017
Price :
$35
*
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- Acronyms NILO-RED
- 26 Dec 2017 New trial record
- 12 Dec 2017 Results (n=67) assessing MMR 12 months after the switch to the once-daily dose-reduced nilotinib regimen presented at the 59th Annual Meeting and Exposition of the American Society of Hematology